<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118532</article-id><article-id pub-id-type="publisher-id">ACM-44718</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_62128047.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  他汀类药物与乳腺癌预后的关系
  The Relationship between Statins and the Prognosis of Breast Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>路</surname><given-names>娜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>淼舟</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青海大学附属医院乳腺疾病诊疗中心，青海 西宁</addr-line></aff><aff id="aff2"><addr-line>青海大学，青海 西宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3632</fpage><lpage>3637</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  他汀类药物是临床上主要应用于针对心血管疾病的降脂药物，近年来，越来越多的研究证实了他汀类降脂药的抗肿瘤作用。在乳腺癌领域，他汀类药物被认为可以降低乳腺癌患者复发风险，降低乳腺癌的死亡率。对于乳腺癌辅助内分泌治疗的患者来说，口服芳香化酶抑制剂导致部分患者血脂异常，从而增加心血管疾病的发生。他汀类药物不仅在降脂上作用显著，其改善乳腺癌患者预后作用意义重大。
   Statins are mainly used clinically as lipid-lowering drugs for cardiovascular diseases. In recent years, more and more studies have confirmed the anti-tumor effects of statins. In the field of breast cancer, statins are believed to reduce the risk of recurrence of breast cancer patients and reduce the mortality rate of breast cancer. For patients undergoing adjuvant endocrine therapy for breast cancer, oral aromatase inhibitors can cause dyslipidemia in some patients, thereby increasing the incidence of cardiovascular disease. Statins not only have a significant effect on lowering lipids, but also have great significance in improving the prognosis of breast cancer patients.
 
</p></abstract><kwd-group><kwd>乳腺癌，他汀类药物，芳香化酶抑制剂, Breast Cancer</kwd><kwd> Statins</kwd><kwd> Aromatase Inhibitors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>他汀类药物是临床上主要应用于针对心血管疾病的降脂药物，近年来，越来越多的研究证实了他汀类降脂药的抗肿瘤作用。在乳腺癌领域，他汀类药物被认为可以降低乳腺癌患者复发风险，降低乳腺癌的死亡率。对于乳腺癌辅助内分泌治疗的患者来说，口服芳香化酶抑制剂导致部分患者血脂异常，从而增加心血管疾病的发生。他汀类药物不仅在降脂上作用显著，其改善乳腺癌患者预后作用意义重大。</p></sec><sec id="s2"><title>关键词</title><p>乳腺癌，他汀类药物，芳香化酶抑制剂</p></sec><sec id="s3"><title>The Relationship between Statins and the Prognosis of Breast Cancer<sup> </sup></title><p>Na Lu<sup>1</sup>, Miaozhou Wang<sup>2*</sup></p><p><sup>1</sup>Qinghai University, Xining Qinghai</p><p><sup>2</sup>Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University, Xining Qinghai</p><p><img src="//html.hanspub.org/file/49-1572500x5_hanspub.png?20210825082308869" /></p><p>Received: Jul. 23<sup>rd</sup>, 2021; accepted: Aug. 15<sup>th</sup>, 2021; published: Aug. 24<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/49-1572500x6_hanspub.png?20210825082308869" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Statins are mainly used clinically as lipid-lowering drugs for cardiovascular diseases. In recent years, more and more studies have confirmed the anti-tumor effects of statins. In the field of breast cancer, statins are believed to reduce the risk of recurrence of breast cancer patients and reduce the mortality rate of breast cancer. For patients undergoing adjuvant endocrine therapy for breast cancer, oral aromatase inhibitors can cause dyslipidemia in some patients, thereby increasing the incidence of cardiovascular disease. Statins not only have a significant effect on lowering lipids, but also have great significance in improving the prognosis of breast cancer patients.</p><p>Keywords:Breast Cancer, Statins, Aromatase Inhibitors</p><disp-formula id="hanspub.44718-formula25"><graphic xlink:href="//html.hanspub.org/file/49-1572500x7_hanspub.png?20210825082308869"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/49-1572500x8_hanspub.png?20210825082308869" /> <img src="//html.hanspub.org/file/49-1572500x9_hanspub.png?20210825082308869" /></p></sec><sec id="s5"><title>1. 引言</title><p>乳腺癌屈居女性癌瘤发病率的首位，其死亡率居于第5位。根据国家癌症中心2015年的数据来看，前十位发病人数的恶性肿瘤中乳腺癌排在第5位，每年新发病人数约为30.4万人。目前发病率每年仍处于上升趋势。即使局部乳腺癌得到有效治疗，5年生存率为99%，但转移性疾病的存在将这一生存率降低到令人沮丧的27% [<xref ref-type="bibr" rid="hanspub.44718-ref1">1</xref>]。乳腺癌的预后与多种因素相关，包括：肿瘤侵犯的范围、临床分期、病理类型和分化程度以及患者身体情况等等。目前据国际癌症组织统计数据来看，乳腺癌患者5年的相对生存率为89.9%，包括：原位癌5年生存率98.8%，早期浸润性乳腺癌85.5%，浸润性乳癌发生转移仅为27.4% [<xref ref-type="bibr" rid="hanspub.44718-ref2">2</xref>]。乳腺癌的转移预示着死亡，因为临床上明显的疾病是侵袭性的并且通常具有化学抗性。现有信息表明，现有治疗疗法无法有效靶向这些微转移灶。因此，防止转移性生长的长期、相对无毒的干预措施将是治疗的进步。流行病学研究发现，他汀类药物可降低乳腺癌死亡率，抑制乳腺癌的进展，以及改善乳腺癌的预后。</p></sec><sec id="s6"><title>2. 辅助内分泌治疗——芳香化酶抑制剂</title><p>辅助内分泌治疗是乳腺癌治疗的重要组成部分，在医疗界受到广泛关注 [<xref ref-type="bibr" rid="hanspub.44718-ref3">3</xref>]。目前国内临床上把第三代芳香化酶抑制剂(甾体芳香化酶抑制剂依西美坦及非甾体芳香化酶抑制剂：来曲唑、阿那曲唑等)主要用于绝经后乳腺癌患者内分泌一线治疗。在相关临床研究中发现，芳香化酶抑制剂在患者服用期间出现多系统不良反应的发生，例：对骨代谢的影响(骨痛、关节痛、肌肉酸痛、骨质疏松和骨折)、心血管影响(血脂异常：高胆固醇血症、高脂血症、心律不齐、心梗、房颤等)、全身反应：(面部潮红/潮热、多汗、水肿等)、肝功能异常(转氨酶、胆红素的升高等)、胃肠道反应(恶心、腹痛、腹泻、便秘等症状)、妇科相关症状(阴道流血、阴道干燥、阴道分泌物增多等)、头面部症状(头痛、头晕、脱发等)、情绪相关症状(易怒、失眠、焦虑、抑郁等)、皮肤反应(皮疹、皮肤瘙痒等)、其他反应(胸痛、呼吸困难、高血压、口干等)。其大多通常为轻度至中度，大多数出现在用药初期，且多为短暂以及耐受的不良反应。值得关注的是长期用药所致的某些不良反应，可能显著影响患者生活质量，甚至有引起较严重并发症的发生 [<xref ref-type="bibr" rid="hanspub.44718-ref4">4</xref>]。其中血脂异常在不良反应中较为常见。对于绝经后女性来说，因卵巢功能减退导致雌激素水平下降，是容易诱发血脂异常的高危因素，同时罹患心血管疾病的风险也增加。一篇关于SWOG临床试验的meta分析中提到从SWOG数据库中入选1460例 &gt; 66岁的乳腺癌患者，其中57%合并有高胆固醇血症 [<xref ref-type="bibr" rid="hanspub.44718-ref5">5</xref>]。以及BIG1-98临床试验、FACE研究及中国医学科学院肿瘤医院进行的大型前瞻性队列研究均证实了芳香化酶抑制剂导致血脂异常不良事件发生的可能性 [<xref ref-type="bibr" rid="hanspub.44718-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.44718-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44718-ref8">8</xref>]。因此临床上对出现血脂异常(高脂血症)的乳腺癌患者通常使用他汀类降脂药物予以对症处理。</p></sec><sec id="s7"><title>3. 他汀类药物分类及抗肿瘤机制</title><sec id="s7_1"><title>3.1. 他汀类药物分类</title><p>他汀类药物(HMG-CoA还原酶(HMGCR)抑制剂)是一种降胆固醇药物，在临床上主要用于治疗心血管疾病已经有30年了，且大多数患者耐受良好 [<xref ref-type="bibr" rid="hanspub.44718-ref9">9</xref>]。其药理作用是通过抑制羟甲基戊二酸单酰辅酶A还原酶(HMG-CoAR)来降低血液中的低密度脂蛋白胆固醇的浓度 [<xref ref-type="bibr" rid="hanspub.44718-ref10">10</xref>]。他汀类药物与HMG-CoAR的活性位点结合的亲和力大约是HMG-CoA本身的1000倍，这导致了他汀类药物与该酶强烈的竞争性抑制，并阻止下游化合物的产生 [<xref ref-type="bibr" rid="hanspub.44718-ref11">11</xref>]。除低密度脂蛋白胆固醇外，这些化合物还包括法尼基焦磷酸(FPP)和香叶基焦磷酸香叶酯(GGPP)。胆固醇是哺乳动物细胞膜的基本结构成分，对细胞增殖至关重要 [<xref ref-type="bibr" rid="hanspub.44718-ref12">12</xref>]。因此他汀类药物抑制内源性胆固醇的产生并阻断蛋白质异戊二烯化，可能会抑制癌症生长和转移所需的细胞增殖 [<xref ref-type="bibr" rid="hanspub.44718-ref13">13</xref>]。</p><p>目前国内临床上他汀类药物有洛伐他汀(第一代)、辛伐他汀(第一代)、普伐他汀(第二代)、氟伐他汀(第二代)、阿托伐他汀(第三代)、瑞舒伐他汀(第三代)和匹伐他汀(第三代)等。他汀类药物之间彼此不同，具有独特的异质性，例：亲脂性、药效学的强度、药动学的参数、适应症、相互作用的多少、肌肉及肝肾毒性的大小等等均不相同。所有他汀类药物都是口服给药，因此30%~85%的摄入剂量被吸收。被吸收的部分在有机阴离子转运蛋白1B1 (OATP1B1)的介导下经历了广泛的首次肝脏摄取 [<xref ref-type="bibr" rid="hanspub.44718-ref14">14</xref>]。其中多根据根据溶解度的差异，将他汀类药物分为亲水性(普伐他汀、瑞舒伐他汀)和亲脂性(洛伐他汀、辛伐他汀、氟伐他汀、阿托伐他汀、匹伐他汀)两种。亲水性更强的他汀类药物主要局限于肝脏，而亲脂性更强的化合物更容易渗透肝外组织 [<xref ref-type="bibr" rid="hanspub.44718-ref15">15</xref>]。因此，亲脂性他汀类药物被认为具有发挥多效性作用的最大潜力，即除了降低LDL胆固醇(低密度脂蛋白胆固醇)之外，还对其他终点产生肝外作用。</p></sec><sec id="s7_2"><title>3.2. 他汀类药物对乳腺癌细胞生物学行为的影响</title><sec id="s7_2_1"><title>3.2.1. 抑制乳腺癌细胞的增殖</title><p>通过降低全身胆固醇水平抑制乳腺癌细胞增殖：HMG-CoAR催化羟甲基戊二酰辅酶A (HMG-CoA)转化为甲羟戊酸，这是甲羟戊酸途径中最终产生胆固醇的限速步骤，他汀类药物抑制此代谢途径将减少了该途径中焦磷酸香叶基香叶酯(GGPP)与法尼基焦磷酸(FPP)等化合物的合成，而这些产物为许多细胞蛋白质翻译后修饰所必需 [<xref ref-type="bibr" rid="hanspub.44718-ref16">16</xref>]，进而影响其细胞生物学的功能，使得细胞G1期和S期细胞数量下降，抑制细胞增殖 [<xref ref-type="bibr" rid="hanspub.44718-ref17">17</xref>]。</p></sec><sec id="s7_2_2"><title>3.2.2. 抑制乳腺癌细胞侵袭和转移</title><p>EMT (上皮–间质转化)为肿瘤侵袭转移的重要机制之一，已有相关研究证实，阿托伐他汀可以通过抑制Ras癌基因活性，通过PI3K-Akt (丝氨酸/苏氨酸激酶)信号通路影响下游Akt中介激酶的活性，预防EMT的发生，从而达到降低乳腺癌侵袭转移的能力 [<xref ref-type="bibr" rid="hanspub.44718-ref18">18</xref>]。临床相关动物模型研究证实，辛伐他汀通过抑制NF-κB转录因子(核转录因子κB蛋白)的DNA结合，降低抗凋亡蛋白BCL-XL的表达并增加PTEN (又称为MMAC1，一种抑癌基因)的转录，从而抑制致癌PI3K通路 [<xref ref-type="bibr" rid="hanspub.44718-ref19">19</xref>] 达到抑制肿瘤侵袭和转移的目的。</p></sec><sec id="s7_2_3"><title>3.2.3. 诱导细胞凋亡</title><p>Gopalan等 [<xref ref-type="bibr" rid="hanspub.44718-ref20">20</xref>] 证明辛伐他汀抑制甲羟戊酸途径(HMG-CoA还原酶及其中间体GGPP)上调死亡受体DR5、人乳腺癌细胞系CCAAT/增强子结合蛋白同源蛋白(CHOP)和磷酸化c-JunN末端激酶(pJNK)的表达来诱导肿瘤细胞凋亡，证明了辛伐他汀诱导的细胞凋亡在JNK/CHOP/DR5信号通路中的重要性。</p></sec><sec id="s7_2_4"><title>3.2.4. 通过异戊二烯化依赖性蛋白质中断致癌信号</title><p>前文提及的FPP是一种由甲羟戊酸产生的类异戊二烯，是合成胆固醇和GGPP的起始材料。FPP和GGPP翻译后对几种蛋白质异戊二烯化，以确保它们正确的细胞内定位和功能。值得注意的是，RAS癌基因超家族的成员正是依赖异戊二烯化才能成功放置在质膜中 [<xref ref-type="bibr" rid="hanspub.44718-ref17">17</xref>]。因此减少异戊二烯化对于他汀类药物的免疫调节起关键作用，可抑制炎症(防止形成促癌环境的生长因子和细胞因子)和增强免疫系统先天性和适应性部分的抗肿瘤反应 [<xref ref-type="bibr" rid="hanspub.44718-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.44718-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.44718-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.44718-ref24">24</xref>]。因此，通过FPP和GGPP消耗破坏蛋白质异戊二烯化是一种有吸引力的化学预防策略。</p></sec></sec></sec><sec id="s8"><title>4. 他汀药物改善乳腺癌预后的相关循证学依据</title><p>一项丹麦大型回顾性的全国性研究，评估了1995年至2007年间被诊断为癌症的整个丹麦人群的死亡率，对比了在40岁或以上的在癌症诊断前定期使用他汀类药物与从未使用过他汀类药物的患者，其结果显示与从未使用过他汀类药物的人相比，他汀类药物使用者的癌症相关死亡率在13种癌症类型中均有所降低。从而证实了他汀类药物的使用与癌症死亡率的降低有关 [<xref ref-type="bibr" rid="hanspub.44718-ref25">25</xref>]。而在乳腺癌中，他汀类药物的抗增殖作用已在亲脂性 [<xref ref-type="bibr" rid="hanspub.44718-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.44718-ref27">27</xref>] 和亲水性他汀类药物 [<xref ref-type="bibr" rid="hanspub.44718-ref28">28</xref>] 的乳腺癌临床试验中得到证实，此项试验证实对亲脂性他汀类药物(如辛伐他汀)的作用特别强。在芬兰一项针对新诊断的乳腺癌患者的大型研究中，观察到乳腺癌特异性死亡率显著降低 54%，这与亲水性和亲脂性他汀类药物的剂量依赖性相似 [<xref ref-type="bibr" rid="hanspub.44718-ref29">29</xref>]。其第二项研究纳入了在英格兰诊断出的乳腺癌患者，他汀类药物使用者乳腺癌死亡率降低了16%，但不显著，但对于高度亲脂性的辛伐他汀来说似乎更显着 [<xref ref-type="bibr" rid="hanspub.44718-ref30">30</xref>]。在丹麦对诊断为I~III期乳腺癌的女性进行的一项大型队列研究中，在诊断后使用他汀类药物的患者中观察到癌症复发风险降低20%。在亲脂性他汀类药物使用者中也观察到乳腺癌复发率降低，而亲水性他汀类药物未观察到相关性 [<xref ref-type="bibr" rid="hanspub.44718-ref31">31</xref>]。一篇英国癌症杂志发表的匹兹堡大学一项动物实验文章也表明，他汀类药物可以直接影响乳腺癌细胞的增殖，特别是在转移部位阻断转移性肿瘤的生长，可考虑作为乳腺癌长期辅助药物使用，以延迟乳腺癌转移，以及降低乳腺癌患者死亡率。</p></sec><sec id="s9"><title>5. 小结</title><p>综上所述，越来越多的临床研究及试验证实了他汀类药物的抗肿瘤作用，进一步证实了他汀类降脂药可以降低乳腺癌的复发风险以及降低肿瘤相关的死亡率。临床医师在临床诊疗过程中，对乳腺癌口服芳香化酶抑制剂患者除了预防其不良事件的发生，应有意识的将他汀类药物作为辅助用药改善其预后。</p></sec><sec id="s10"><title>文章引用</title><p>路 娜,王淼舟. 他汀类药物与乳腺癌预后的关系The Relationship between Statins and the Prognosis of Breast Cancer[J]. 临床医学进展, 2021, 11(08): 3632-3637. https://doi.org/10.12677/ACM.2021.118532</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44718-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Beckwitt, C.H., Clark, A.M., Ma, B., Whaley, D., Oltvai, Z.N. and Wells, A. (2018) Statins Attenuate Outgrowth of Breast Cancer Metastases. British Journal of Cancer, 119, 1094-1105. &lt;br&gt;https://doi.org/10.1038/s41416-018-0267-7</mixed-citation></ref><ref id="hanspub.44718-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Yousef, A. and Jad, A. (2017) Male Breast Cancer: Epidemiology and Risk Factors. Seminars in Oncology, 44, 267-272.</mixed-citation></ref><ref id="hanspub.44718-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王芹, 李德俊, 吴玉萍. 内分泌治疗对绝经后乳腺癌患者血脂和骨骼健康的影响[J]. 中国当代医药, 2018, 25(29): 46-48.</mixed-citation></ref><ref id="hanspub.44718-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">于世英. 长期服用芳香化酶抑制剂的不良反应处理[C]//中国癌症基金会、中国抗癌协会肿瘤临床化疗专业委员会、中华医学会肿瘤学分会、全国肿瘤防治研究办公室、中国医学科学院肿瘤医院. 第三届中国肿瘤内科大会教育集暨论文集. 2009: 216-218.</mixed-citation></ref><ref id="hanspub.44718-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hershman, D.L., Till, C., Shen, S., et al. (2018) Association of Cardiovascular Risk Factors with Cardiac Events and Survival Outcomes among Patients with Breast Cancer Enrolled in SWOG Clinical Trials. Journal of Clinical Oncology, 36, 2710-2717. &lt;br&gt;https://doi.org/10.1200/JCO.2017.77.4414</mixed-citation></ref><ref id="hanspub.44718-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mauriac, L., Keshaviah, A., Debled, M., Mouridsen, H., Forbes, J.F., Thürlimann, B., Paridaens, R., Monnier, A., Láng, I., Wardley, A., Nogaret, J.M., Gelber, R.D., Castiglione-Gertsch, M., Price, K.N., Coates, A.S., Smith, I., Viale, G., Rabaglio, M., Zabaznyi, N., Goldhirsch, A., BIG 1-98 Collaborative Group and International Breast Cancer Study Group (2007) Predictors of Early Relapse in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer in the BIG 1-98 Trial. Annals of Oncology, 18, 859-867. &lt;br&gt;https://doi.org/10.1093/annonc/mdm001</mixed-citation></ref><ref id="hanspub.44718-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Smith, I., Yardley, D., Burris, H., et al. (2017) Comparative Efficacy and Safety of Adjuvant Letrozole versus Anastrozole in Postmenopausal Patients with Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara versus Anastrozole Clinical Evaluation (FACE) Trial. Journal of Clinical Oncology, 35, 1041-1048.</mixed-citation></ref><ref id="hanspub.44718-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Zhu, A.J., Wang, J.Y., et al. (2020) Steroidal Aromatase Inhibitors Have a More Favorable Effect on Lipid Profiles than Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Early Breast Cancer: A Prospective Cohort Study. Therapeutic Advances in Medical Oncology, 12. &lt;br&gt;https://doi.org/10.1177/1758835920925991</mixed-citation></ref><ref id="hanspub.44718-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Endo, A. (2008) A Gift from Nature: The Birth of the Statins. Nature Medicine, 14, 1050-1052.  
&lt;br&gt;https://doi.org/10.1038/nm1008-1050</mixed-citation></ref><ref id="hanspub.44718-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ahern, T.P., Lash, T.L., Damkier, P., Christiansen, P.M. and Cronin-Fenton, D.P. (2014) Statins and Breast Cancer Prognosis: Evidence and Opportunities. The Lancet Oncology, 15, e461-e468.  
&lt;br&gt;https://doi.org/10.1016/S1470-2045(14)70119-6</mixed-citation></ref><ref id="hanspub.44718-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Bersot, T. (2011) Drug Therapy for Hypercholesterolemia and Dyslipidemia. In: Brunton, L.L., Chabner, B.A. and Knollman, B.C., Eds., Goodman &amp; Gilman’s the Pharmacological Basis of Therapeutics, 12th Edition, McGraw-Hill, New York, 933-966.</mixed-citation></ref><ref id="hanspub.44718-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lamond, A.I. (2002) Review of: Molecular Biology of the Cell, 4th Edition. Nature, 417, 383.  
&lt;br&gt;https://doi.org/10.1038/417383a</mixed-citation></ref><ref id="hanspub.44718-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Rosch, P.J. and McCully, K. (2013) Statin Use and Reduced Cancer-Related Mortality. The New England Journal of Medicine, 368, 576. &lt;br&gt;https://doi.org/10.1056/NEJMc1214827</mixed-citation></ref><ref id="hanspub.44718-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Niemi, M., Pasanen, M.K. and Neuvonen, P.J. (2011) Organic Anion Transporting Polypeptide 1B1: A Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews, 63, 157-181.  
&lt;br&gt;https://doi.org/10.1124/pr.110.002857</mixed-citation></ref><ref id="hanspub.44718-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">孙忠实. 关于他汀类药若干争议的思考——从临床药理学角度诠释[J]. 中国医院用药评价与分析, 2014, 14(2): 97-99.</mixed-citation></ref><ref id="hanspub.44718-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">闫冰. 辛伐他汀联合紫杉醇靶向作用Hippo信号通路对乳腺癌干细胞的影响[D]: [硕士学位论文]. 大连: 大连医科大学, 2017.</mixed-citation></ref><ref id="hanspub.44718-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Crescencio, M.E., Rodríguez, E., Páez, A., et al. (2009) Statins Inhibit the Proliferation and Induce Cell Death of Human Papilloma Virus Positive and Negative Cervical Cancer Cells. International Journal of Biomedical Science, 5, 411-420.</mixed-citation></ref><ref id="hanspub.44718-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Beckwitt, C.H., Shiraha, K. and Wells, A. (2018) Lipophilic Statins Limit Cancer Cell Growth and Survival, via Involvement of Akt Signaling. PLoS ONE, 13, e0197422. &lt;br&gt;https://doi.org/10.1371/journal.pone.0197422</mixed-citation></ref><ref id="hanspub.44718-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ghosh-Choudhury, N., Mandal, C.C., Ghosh-Choudhury, N. and Ghosh Choudhury, G. (2010) Simvastatin Induces Derepression of PTEN Expression via NFkappaB to Inhibit Breast Cancer Cell Growth. Cell Signal, 22, 749-758.  
&lt;br&gt;https://doi.org/10.1016/j.cellsig.2009.12.010</mixed-citation></ref><ref id="hanspub.44718-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Gopalan, A., Yu, W., Sanders, B.G., et al. (2013) Simvastatin Inhibition of Mevalonate Pathway Induces Apoptosis in Human Breast Cancer Cells via Activation of jnk/chop/dr5 Signaling Pathway. Cancer Letters, 329, 9-16.  
&lt;br&gt;https://doi.org/10.1016/j.canlet.2012.08.031</mixed-citation></ref><ref id="hanspub.44718-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Benn, M., Tybjærg-Hansen, A., Stender, S., Frikke-Schmidt, R. and Nordestgaard, B.G. (2011) Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study. Journal of the National Cancer Institute, 103, 508-519. &lt;br&gt;https://doi.org/10.1093/jnci/djr008</mixed-citation></ref><ref id="hanspub.44718-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Thurnher, M., Gruenbacher, G. and Nussbaumer, O. (2013) Regulation of Mevalonate Metabolism in Cancer and Immune Cells. Biochimica et Biophysica Acta, 1831, 1009-1015. &lt;br&gt;https://doi.org/10.1016/j.bbalip.2013.03.003</mixed-citation></ref><ref id="hanspub.44718-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Clendening, J.W., Pandyra, A., Boutros, P.C., et al. (2010) Dysregulation of the Mevalonate Pathway Promotes Transformation. Proceedings of the National Academy of Sciences of the United States of America, 107, 15051-15056.  
&lt;br&gt;https://doi.org/10.1073/pnas.0910258107</mixed-citation></ref><ref id="hanspub.44718-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Borgquist, S., Jögi, A., Pontén, F., Rydén, L., Brennan, D.J. and Jirström, K. (2008) Prognostic Impact of Tumour-Specific HMG-CoA Reductase Expression in Primary Breast Cancer. Breast Cancer Research, 10, R79.  
&lt;br&gt;https://doi.org/10.1186/bcr2146</mixed-citation></ref><ref id="hanspub.44718-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Nielsen, S.F., Nordestgaard, B.G. and Bojesen, S.E. (2012) Statin Use and Reduced Cancer-Related Mortality. The New England Journal of Medicine, 368, 576-577. &lt;br&gt;https://doi.org/10.1056/NEJMoa1201735</mixed-citation></ref><ref id="hanspub.44718-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Garwood, E.R., Kumar, A.S., Baehner, F.L., et al. (2010) Fluvastatin Reduces Proliferation and Increases Apoptosis in Women with High Grade Breast Cancer. Breast Cancer Research and Treatment, 119, 137-144.  
&lt;br&gt;https://doi.org/10.1007/s10549-009-0507-x</mixed-citation></ref><ref id="hanspub.44718-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Bjarnadottir, O., Romero, Q., Bendahl, P.-O., et al. (2013) Targeting HMG-CoA Reductase with Statins in a Window-of-Opportunity Breast Cancer Trial. Breast Cancer Research and Treatment, 138, 499-508.  
&lt;br&gt;https://doi.org/10.1007/s10549-013-2473-6</mixed-citation></ref><ref id="hanspub.44718-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Bjarnadottir, O., Kimburg, S., Johansson, I., et al. (2015) Global Transcriptional Changes Following Statin Treatment in Breast Cancer. Clinical Cancer Research, 21, 3402-3411. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-14-1403</mixed-citation></ref><ref id="hanspub.44718-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Murtola, T.J., Visvanathan, K., Artama, M., Vainio, H. and Pukkala, E. (2014) Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland. PLoS ONE, 9, e110231. &lt;br&gt;https://doi.org/10.1371/journal.pone.0110231</mixed-citation></ref><ref id="hanspub.44718-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Cardwell, C.R., Hicks, B.M. and Hughes, C.M.L. (2015) Statin Use after Diagnosis of Breast Cancer and Survival: A Population-Based Cohort Study. Epidemiology, 26, 68-78. &lt;br&gt;https://doi.org/10.1097/EDE.0000000000000189</mixed-citation></ref><ref id="hanspub.44718-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Ahern, T.P., Pedersen, L., Tarp, M., et al. (2011) Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study. Journal of the National Cancer Institute, 103, 1461-1468.  
&lt;br&gt;https://doi.org/10.1093/jnci/djr291</mixed-citation></ref></ref-list></back></article>